Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Ipatasertib Market Poised To Hit $1.6 Billion By 2030 With A 13.1% CAGR
The ipatasertib market has experienced rapid growth in recent years. It is projected to increase from $0.86 billion in 2025 to $0.98 billion in 2026, at a compound annual growth rate (CAGR) of 13.4%. The growth observed in the past can be ascribed to advancements in pi3k/akt pathway research, the increasing prevalence of advanced-stage cancers, the expansion of targeted oncology drug pipelines, the proliferation of clinical trials for small-molecule inhibitors, and a rising adoption of precision oncology approaches.
The ipatasertib market is anticipated to show significant expansion over the coming years, with its size projected to reach $1.6 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.1%. This expansion during the forecast period is propelled by factors such as increasing regulatory approvals for targeted cancer drugs, a growing demand for personalized cancer therapies, the broadening of combination therapy strategies, rising investments in oncology research and development, and an intensified focus on treatment options for resistant cancers. Furthermore, significant trends shaping this period include a heightened emphasis on AKT pathway inhibition therapies, a growing adoption of combination cancer treatment regimens, an increased focus on biomarker-driven oncology drugs, the expansion of targeted small-molecule pipelines, and enhanced clinical evaluations of precision oncology agents.
Get A Free Sample Report With In-Depth Market Insights:
Ipatasertib Market Growth Factors: What’s Supporting Expansion?
The increasing incidence of cancer is projected to fuel the expansion of the ipatasertib market moving forward. Cancer describes a variety of conditions characterized by the unchecked proliferation and dissemination of atypical cells within the body. The rising occurrence of cancer stems from lifestyle choices such as poor nutrition, smoking, lack of physical activity, and excessive alcohol intake. Ipatasertib enhances cancer treatment strategies by targeting the PI3K/AKT signaling pathway, thereby effectively hindering tumor growth and multiplication. It reduces the viability of cancer cells and their resistance to therapy, leading to improved treatment results and patient outlook. For instance, in April 2024, data from the American Cancer Society (ACS) and the International Agency for Research on Cancer (IARC) showed 20 million new cancer cases in 2022, surpassing previous estimates, with projections indicating 35 million by 2050, representing a 77% increase. Hence, the growing prevalence of cancer is driving the growth of the ipatasertib market.
Ipatasertib Market Segment Outlook: Which Categories Are Growing Fastest?
The ipatasertib market covered in this report is segmented –
1) By Indication: Prostate Cancer, Breast Cancer, Other Cancers
2) By Dosage Form: Tablets, Capsules, Other Dosages
3) By Route Of Administration: Oral, Intravenous
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Prostate Cancer: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Non-Metastatic Prostate Cancer
2) By Breast Cancer: Triple-Negative Breast Cancer (TNBC), Hormone Receptor-Positive Or Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
3) By Other Cancers: Ovarian Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Lung Cancer
Ipatasertib Market Leading Companies And Competitive Benchmarking
Major companies operating in the ipatasertib market are Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., BGI Genomics Co. Ltd., Invitae Corporation, Guardant Health Inc., GeneDx LLC, Ancestry Inc., Oxford Nanopore Technologies plc, Genomic Health Inc., 23andMe Holding Co., Color Health Inc., Helix OpCo LLC, Personalis Inc., Dante Genomics, Gene By Gene Ltd., Veritas Genetics Inc., Futura Genetics, Nebula Genomics Inc., Pathway Genomics Corporation
View The Full Ipatasertib Market Report:
Ipatasertib Market Global Footprint: Which Region Leads The Industry?
North America was the largest region in the ipatasertib market in 2025. The regions covered in the ipatasertib market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model